JP2017531646A5 - - Google Patents

Download PDF

Info

Publication number
JP2017531646A5
JP2017531646A5 JP2017518070A JP2017518070A JP2017531646A5 JP 2017531646 A5 JP2017531646 A5 JP 2017531646A5 JP 2017518070 A JP2017518070 A JP 2017518070A JP 2017518070 A JP2017518070 A JP 2017518070A JP 2017531646 A5 JP2017531646 A5 JP 2017531646A5
Authority
JP
Japan
Prior art keywords
hal
cor
conr
independently
atoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017518070A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017531646A (ja
JP6662865B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2015/001973 external-priority patent/WO2016050358A1/en
Publication of JP2017531646A publication Critical patent/JP2017531646A/ja
Publication of JP2017531646A5 publication Critical patent/JP2017531646A5/ja
Application granted granted Critical
Publication of JP6662865B2 publication Critical patent/JP6662865B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017518070A 2014-10-01 2015-10-01 ボロン酸誘導体 Active JP6662865B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14003389.5 2014-10-01
EP14003389 2014-10-01
PCT/EP2015/001973 WO2016050358A1 (en) 2014-10-01 2015-10-01 Boronic acid derivatives

Publications (3)

Publication Number Publication Date
JP2017531646A JP2017531646A (ja) 2017-10-26
JP2017531646A5 true JP2017531646A5 (enExample) 2019-10-17
JP6662865B2 JP6662865B2 (ja) 2020-03-11

Family

ID=51751859

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017518070A Active JP6662865B2 (ja) 2014-10-01 2015-10-01 ボロン酸誘導体

Country Status (21)

Country Link
US (1) US10669289B2 (enExample)
EP (1) EP3201206B1 (enExample)
JP (1) JP6662865B2 (enExample)
KR (1) KR102457840B1 (enExample)
CN (1) CN107001391B (enExample)
AU (1) AU2015327345B9 (enExample)
BR (1) BR112017006622A2 (enExample)
CA (1) CA2963203A1 (enExample)
CL (1) CL2017000792A1 (enExample)
DK (1) DK3201206T3 (enExample)
ES (1) ES2761774T3 (enExample)
IL (1) IL251302B (enExample)
MX (1) MX372823B (enExample)
MY (1) MY186911A (enExample)
NZ (1) NZ730981A (enExample)
PH (1) PH12017500293A1 (enExample)
RU (1) RU2717558C2 (enExample)
SG (1) SG11201702628XA (enExample)
UA (1) UA122672C2 (enExample)
WO (1) WO2016050358A1 (enExample)
ZA (1) ZA201703007B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9453018B2 (en) 2014-10-01 2016-09-27 Bristol-Myers Squibb Company Pyrimidinones as factor XIa inhibitors
EP3201208B1 (en) 2014-10-01 2021-03-24 Merck Patent GmbH Boronic acid derivatives
US10294246B2 (en) 2014-10-01 2019-05-21 Merck Patent Gmbh Substituted boronic acids and boronate esters as immunoproteasome inhibitors
EP3201205B1 (en) 2014-10-01 2020-05-13 Merck Patent GmbH Boronic acid derivatives
PT3571208T (pt) 2017-01-18 2021-04-13 Principia Biopharma Inc Inibidores do imunoproteassoma
US11274109B2 (en) 2017-08-24 2022-03-15 Merck Patent Gmbh Boronic acid derivatives
WO2019042301A1 (zh) * 2017-08-29 2019-03-07 浙江海正药业股份有限公司 (E)-α,β-不饱和酰胺化合物及其制备方法和用途
EP3694528A4 (en) * 2017-10-13 2021-07-28 The Regents of the University of California MTORC1 MODULATORS
EP3710458B1 (en) * 2017-11-16 2026-03-25 Principia Biopharma Inc. Immunoproteasome inhibitors
ES2928787T3 (es) * 2017-11-16 2022-11-22 Principia Biopharma Inc Inhibidores del inmunoproteasoma
IL280376B2 (en) 2018-07-26 2024-08-01 Merck Patent Gmbh Boronic acid derivatives, their preparation and pharmaceutical compositions containing them
CN113135944A (zh) * 2020-01-19 2021-07-20 首药控股(北京)有限公司 硼酸衍生物
CN113135943A (zh) * 2020-01-19 2021-07-20 首药控股(北京)有限公司 硼酸衍生物
EP4377324A1 (en) 2021-07-29 2024-06-05 Merck Patent GmbH Novel crystalline forms of [(1r)-2-(1-benzofuran-3-yl)-1-{[(1s,2r,4r)-7- oxabicyclo[2.2.1]heptan-2-yl]formamido}ethyl]boronic acid, adducts thereof, and processes to obtain
US20240425529A1 (en) * 2021-10-14 2024-12-26 Shouyao Holdings (beijing) Co., Ltd. Boric acid derivative
WO2023232830A1 (en) 2022-06-02 2023-12-07 Merck Patent Gmbh Boronic acid adducts

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5658885A (en) * 1993-04-27 1997-08-19 The Dupont Merck Pharmaceutical Company Amidino and guanidino substituted boronic acid inhibitors of trypsin-like enzymes
IL111175A0 (en) 1993-10-07 1994-12-29 Du Pont Merck Pharma Electrophilic peptide analogs as inhibitors of trypsin-like serine proteases and pharmaceutical compositions containing them
US5462964A (en) * 1993-10-20 1995-10-31 The Du Pont Merck Pharmaceutical Company Dipeptide boronic acid inhibitors of trypsin-like enzymes
AU5920400A (en) * 1999-07-07 2001-01-22 Du Pont Pharmaceuticals Company Cell-based assay systems for examining hcv ns3 protease activity
BR0314450A (pt) * 2002-09-09 2005-07-26 Trigen Ltd Sais de ácido borÈnico com adição de uma base farmaceuticamente aceitável, formulação farmacêutica, e uso dos referidos sais para preparar uma formulação farmacêutica
UA88771C2 (ru) * 2003-08-14 2009-11-25 Сефалон, Инк. Ингибиторы протеасомы и способ их применения (варианты)
US7576206B2 (en) * 2003-08-14 2009-08-18 Cephalon, Inc. Proteasome inhibitors and methods of using the same
AR075090A1 (es) * 2008-09-29 2011-03-09 Millennium Pharm Inc Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden.
SG10201503168VA (en) 2010-04-22 2015-06-29 Mars Inc Inhibitors of arginase and their therapeutic applications
SG11201403254QA (en) 2011-12-22 2014-07-30 Ares Trading Sa Alpha-amino boronic acid derivatives, selective immunoproteasome inhibitors
SG10201908467RA (en) 2014-01-31 2019-10-30 Bristol Myers Squibb Co Macrocycles with hetrocyclic p2' groups as factor xia inhibitors
MX2017004298A (es) 2014-10-01 2017-07-19 Janssen Pharmaceuticals Inc Indoles mono o disustituidos como inhibidores de la replicacion del virus del denge.
US10294246B2 (en) 2014-10-01 2019-05-21 Merck Patent Gmbh Substituted boronic acids and boronate esters as immunoproteasome inhibitors
EP3201208B1 (en) 2014-10-01 2021-03-24 Merck Patent GmbH Boronic acid derivatives
ME03360B (me) 2014-10-01 2019-10-20 Janssen Pharmaceuticals Inc Mono- ili di-supsтituisani derivaтi indola као inhibiтori replikacije virusa denge
EP3201205B1 (en) 2014-10-01 2020-05-13 Merck Patent GmbH Boronic acid derivatives
NO2721243T3 (enExample) 2014-10-01 2018-10-20

Similar Documents

Publication Publication Date Title
JP2017531646A5 (enExample)
JP2018502048A5 (enExample)
JP2017536335A5 (enExample)
AR122783A2 (es) Inhibidores de kras g12c y métodos para su uso
AR104963A1 (es) Derivados de 2-(pirazolopiridin-3-il)pirimidina como inhibidores de jak
MX380928B (es) Inhibidores de kras g12c.
EA201891191A1 (ru) 2-замещенные соединения хиназолина, содержащие замещенную гетероциклическую группу, и способы их применения
CO2018004800A2 (es) Antagonistas del receptor muscarinico 4 y metodos de uso.
MX2021014177A (es) Inhibidores de kras con la mutacion de glicina a cisteina en el codon 12 (g12c) y usos de los mismos.
CO2022002842A2 (es) Degradadores bifuncionales de brd9 y sus métodos de uso
CY1123451T1 (el) Αγωνιστες τριαζολης του υποδοχεα αρj
JP2016515561A5 (enExample)
CO2020000194A2 (es) Inhibidores de quinasa alk2 que contienen imidazol
CL2019002150A1 (es) Derivados de 3-fenil-4-amino-imidazo[4,5-c]piridin-2-ona y 7-fenil-6-amino-purin-8-ona sustituidos, inhibidores de tirosinacinasas, en particular tirosinacinasa de bruton (btk); composiciones que contiene los compuestos; y uso para enfermedades tales como cáncer, autoinmunitarias, inflamatorias y tromboembólicas. (divisional solicitud 201703073)
MX2021000887A (es) Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer.
CL2018003060A1 (es) Compuestos de pirimidina como inhibidores de la quinasa jak.
WO2017205536A3 (en) Heterocyclic inhibitors of cbp/ep300 and their use in the treatment of cancer
CY1124680T1 (el) Παραγωγα 8-[6-[3-(αμινο)προποξυ]-3-πυριδυλο]-1-ισοπροπυλο-ιμιδαζο[4,5-c]κινολιν-2-ονης ως εκλεκτiκοι ρυθμιστες κινασης μεταλλαγμενης αταξιας τελαγγειεκτασιας (atm) για τη θεραπευτικη αγωγη του καρκινου
CY1119771T1 (el) Ενωσεις αμινοπυριμιδινυλιου ως αναστολεις toy jak
MX2019013954A (es) Inhibidores covalentes de kras.
WO2016164675A8 (en) Substituted quinazoline compounds and methods of use thereof
AR088748A1 (es) Macrociclos como inhibidores del factor xia
AR099228A1 (es) Inhibidores macrocíclicos de fxia que tienen grupos heterocíclicos
AR117189A1 (es) Derivados de 6,7-dihidro-4h-pirazolo[1,5-a]pirazin indol-2-carboxamidas activos contra el virus de la hepatitis b (vhb)
EA201991884A2 (ru) Ингибиторы g12c kras